JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (4)
2022
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
The New England journal of medicine, Vol. 386, Núm. 26, pp. 2482-2494
-
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
HemaSphere
2019
-
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11
-
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis
Haematologica